Haemonetics account plan
Medical products development
At a glance
Haemonetics is a Boston-based medical technology company in plasma collection, apheresis and hospital devices, with $1,334.0 million fiscal 2026 revenue.
Haemonetics is a Boston-based medical technology company that sells plasma collection systems to biopharmaceutical plasma fractionators, apheresis products to blood centers, and hospital technologies (vascular closure, sensor-guided guidewires, hemostasis testing, cell salvage, transfusion software) in approximately 90 countries. Its model is largely razor/razor-blade: devices, mostly built by contract manufacturers, plus consumables it largely makes itself in North America and Malaysia. In fiscal 2026 (52 weeks to March 28, 2026) net revenues were $1,334.0 million (down 2.0%), operating income $156.7 million and net income $97.3 million, with 73.6% of revenue in the United States. It employed 3,009 full-time equivalent people at March 28, 2026, about 78% in North America. Since June 5, 2026 it reports two segments, Apheresis and MedSurg; Christopher A. Simon is President and Chief Executive Officer.
Business units
Apheresis (Plasma)
Q2 fiscal 2027 revenue $162.6 million (+16.5%); about 80% of ApheresisAutomated plasma collection devices (NexSys PCS with Persona and Persona PLUS), disposables and donor management software (NexLynk DMS) sold to source plasma collectors such as Grifols, Octapharma, Takeda's BioLife and CSL. Under the 10-K's former structure Plasma was 39.3% of fiscal 2026 revenue ($524.5 million). Q2 fiscal 2027 growth came from volume growth, share gains and the Persona PLUS rollout.
Apheresis (Other, former Blood Center)
Q2 fiscal 2027 revenue $42.2 million, flatAutomated blood component collection systems for blood centers: MCS apheresis equipment for platelets, plasma and red cells, and the ACP automated cell processor. Blood Center was 16.6% of fiscal 2026 revenue ($221.3 million, -15.3%) after the Whole Blood line was divested in Q4 fiscal 2025. Mature markets are expected to be stable to slightly declining, with growth in emerging markets.
MedSurg - Blood Management Technologies
Q2 fiscal 2027 revenue $92.4 million (+7.0%)Hemostasis Management (TEG 6s analyzer and cartridges), Cell Salvage (Cell Saver Elite+) and Transfusion Management software (SafeTrace Tx, BloodTrack), sold to surgeons, anesthesiologists and hospital blood banks. Fiscal 2026 revenue was $354.3 million (+14.6%). Transfusion Management is now 20% of BMT revenue; TEG revenue splits 85/15 disposables to capital.
MedSurg - Interventional Technologies
Q2 fiscal 2027 revenue $60.5 million (+2.4%)Vascular closure (VASCADE MVP and MVP XL, PerQseal Elite large-bore closure from Vivasure), sensor-guided guidewires (OptoWire, SavvyWire, PacePro) and esophageal protection (ensoETM from Attune Medical), sold to interventional cardiology and electrophysiology labs. Fiscal 2026 revenue was $234.0 million (-8.2%) as esophageal cooling demand fell with the shift to pulsed field ablation.
Strategic priorities
- Grow Plasma through the CSL rollout and Persona PLUS
- An August 14, 2026 non-exclusive supply agreement lets CSL Plasma use NexSys PCS with Persona PLUS; Haemonetics expects to complete the rollout to all CSL U.S. centers before the end of calendar 2027, adding approximately 50% more volume to Plasma. Persona PLUS delivers roughly an additional 5% yield per donation.
- Shift the portfolio to higher-growth, higher-margin lines
- Management sees Plasma and Hospital (now MedSurg) as the growth engines; Whole Blood was divested and Blood Center is focused on plasma and platelets. Gross margin rose to 59.0% in fiscal 2026 from 55.0%.
- Launch new MedSurg products
- Fiscal 2027 is called the year of launch: the VASCADE MVP XL expanded label (CE Mark and Japanese approval), the PacePro TAVR guidewire, and FDA approval of PerQseal Elite in October 2026 for a large-bore closure market sized at $300 million. These launches are not expected to contribute materially to fiscal 2027 revenue.
- Expand operating margins over time
- Management aims for high 20s operating margins or better as the business scales, with margin gains expected in fiscal 2028 after transitory production and freight costs.
- Focus resources on the fastest-growing markets
- A market and regional alignment initiative approved in May 2025 directs resources to the markets and geographies with the greatest growth; cumulative costs reached $7.9 million by the first half of fiscal 2027.
- Capital allocation: organic first, then debt and buybacks
- Organic investment comes first, then debt paydown; $325.0 million remains under the April 2025 buyback program and $100.0 million of revolver borrowings were repaid in the first half of fiscal 2027.
Latest results
In Q2 fiscal 2027 (quarter ended September 26, 2026) net revenues rose 9.3% to $357.8 million (10.0% organic), with Apheresis at $204.8 million (+12.6%) and MedSurg at $153.0 million (+5.1%). Plasma grew 16.5% on volume growth and share gains. Gross margin reached 61.7% (59.5% a year earlier), helped by tariff refunds, and operating income rose 28.4% to $75.1 million; diluted EPS was $1.00 (adjusted EPS $1.35). First-half revenue was $697.1 million (+7.5%) and first-half operating cash flow $180.4 million (vs $128.7 million). Fiscal 2027 guidance was raised to 8-11% reported and 6-9% organic revenue growth, while adjusted operating margin expansion was cut to 0-50 bps on personnel costs, performance pay and freight.
Investments and deals
- Vivasure acquisition
- Acquired Vivasure (Galway, PerQseal Elite large-bore closure) on January 9, 2026; the purchase price is now stated as $166.0 million. It extends vascular closure into large-bore TAVR, EVAR and mechanical circulatory support procedures.
- New capex cycle for the CSL ramp
- The CSL ramp will start a new capex cycle, with elevated capital expenditures over the next two years for manufacturing lines, packaging, warehousing and devices; production is rising by over 40%. First-half fiscal 2027 capex was $22.7 million.
- Global ERP and digital transformation
- A new global ERP system is being implemented, with $21.5 million of digital transformation costs in fiscal 2026.
- Debt refinancing and buybacks
- The $300.0 million 2026 convertible notes were repaid on March 2, 2026; $175.0 million of shares were repurchased in fiscal 2026. Net debt fell to $863.0 million at September 26, 2026 from $979.1 million at March 28, 2026.
Challenges and risks
- Plasma customer concentration
- The ten largest customers were about 44% of fiscal 2026 net revenues and one Plasma customer about 13%; the CSL agreement is non-exclusive with no minimum purchase commitments.
- Esophageal cooling and goodwill headroom
- Fiscal 2026 carried $86.5 million of intangible impairments, $77.2 million on Attune Medical after pulsed field ablation reduced the esophageal cooling opportunity. Interventional Technologies goodwill headroom is only 6%.
- Cost inflation and tariffs
- Adjusted operating expenses rose 15.2% in Q2 fiscal 2027 on personnel costs and freight; oil, transport and material inflation and tariffs weigh on costs, and supply chain risks include sole-source suppliers and single-site manufacturing.
- Competition
- Plasma and blood center products compete with Fresenius and Terumo BCT and Chinese entrants; patent suits against Terumo BCT and Fresenius Kabi continue. Hospital products face Terumo, Abbott, Cordis, Teleflex, Boston Scientific and Philips.
- Declining blood center markets
- Declining transfusion rates in mature markets and intensified competition in multi-unit collection have weighed on Blood Center growth; Other Apheresis revenue was flat in Q2 fiscal 2027.
What leadership says
“Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities.”
“we're still very confident that this is a business that can deliver high 20s operating margins or better as we scale.”
“Essentially all of our contracts now are global in scope.”
“We started FY27 strong with broad-based execution driving another quarter of profitable growth.”
Where a supplier can help
- Manufacturing and warehousing capacity for the CSL ramp
- The new capex cycle for manufacturing lines, packaging, warehousing and devices opens room for equipment, automation and logistics suppliers supporting the CSL rollout.
- Freight and cost control
- With freight, oil and material inflation cutting margin expansion guidance, suppliers of logistics optimisation, procurement and supply chain resilience can tie their offer to the stated high 20s operating margin aim.
- ERP and digital transformation support
- The global ERP implementation and digital transformation costs point to needs for integration, data migration and IT and cybersecurity services.
- Commercial launch support for MedSurg
- The stepwise PerQseal Elite launch with heavy physician training, and the VASCADE MVP XL and PacePro launches, fit providers of clinical training, medical education and sales enablement.
- Regional go-to-market focus
- The market and regional alignment initiative and global plasma contracts suggest demand for market data, territory planning and international distribution support.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Haemonetics?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for the fiscal year ended March 28, 2026
- Haemonetics is a Boston-based global medical technology company selling plasma collection systems, blood center apheresis products and hospital technologies (vascular closure, sensor-guided guidewires, esophageal protection, hemostasis testing, cell salvage, transfusion software) in approximately 90 countries.
- Fiscal 2026 (52 weeks to March 28, 2026): net revenues $1,334.0 million, down 2.0% (down 2.8% in constant currency), after about $153 million of nonrecurring fiscal 2025 revenue from the CSL Plasma customer transition and the Whole Blood divestiture.
- Gross margin rose to 59.0% from 55.0%, but operating income fell 29.3% to $156.7 million and net income fell 42.0% to $97.3 million (diluted EPS $2.05), mainly on $86.5 million of intangible impairments, largely the Attune Medical (esophageal cooling) asset group hit by the shift to pulsed field ablation.
- Segments in the 10-K: Hospital 44.1% of revenue ($588.3 million, +4.3%), Plasma 39.3% ($524.5 million, -2.0%), Blood Center 16.6% ($221.3 million, -15.3%); management sees Plasma and Hospital as the growth engines.
- Innovation: FDA 510(k) clearance for NexSys PCS with Persona PLUS (mid-single digit percent more plasma per donation over Persona), expanded VASCADE MVP XL label to 10-14F ID / up to 17F OD sheaths used in PFA and LAAC.
- M&A: acquired Vivasure (Galway, PerQseal Elite large-bore closure) on January 9, 2026 for a net purchase price of $164.4 million; PMA filed with FDA for the arterial indication.
- Capital: repaid the $300.0 million 2026 convertible notes at maturity, $175.0 million of buybacks in fiscal 2026 ($325.0 million authorization remaining), $700.0 million 2029 convertible notes outstanding; net debt $979.1 million.
- Customer concentration: ten largest customers about 44% of net revenues; one Plasma customer about 13%. 73.6% of revenue in the United States; 3,009 FTE employees.
- Risks flagged: Interventional Technologies goodwill headroom only 6% (fair value $867.8 million vs carrying $821.6 million), plasma customer concentration, competition from Fresenius, Terumo BCT and Chinese entrants, supply chain, tariffs, new global ERP implementation.
- Form 10-Q for the quarter ended September 26, 2026 (Q2 fiscal 2027)
- Q2 fiscal 2027 (quarter ended September 26, 2026): net revenues $357.8 million, +9.3% (+9.7% constant currency); first half $697.1 million, +7.5%.
- New segment structure from June 5, 2026: Apheresis (Plasma + former Blood Center) and MedSurg (former Hospital).
- Apheresis Q2 revenue $204.8 million (+12.6%), with Plasma $162.6 million (+16.5%) on volume growth and share gains; Other Apheresis flat at $42.2 million.
- MedSurg Q2 revenue $153.0 million (+5.1%): Blood Management Technologies $92.4 million (+7.0%), Interventional Technologies $60.5 million (+2.4%).
- Gross margin 61.7% (59.5%), helped by tariff refunds; operating income $75.1 million (+28.4%, 21.0% margin); net income $46.3 million; diluted EPS $1.00.
- August 14, 2026 non-exclusive supply agreement with CSL Plasma for NexSys PCS with Persona PLUS; CSL expects to complete the rollout at all its current U.S. centers by end of calendar 2027.
- FDA approved PerQseal Elite for large-bore arterial procedures in October 2026.
- Revolver cut from $300.0 million to $200.0 million in the first half; cash $260.7 million; net debt $863.0 million.
- First-half operating cash flow $180.4 million (vs $128.7 million).
- Haemonetics Reports Second Quarter and First Half Fiscal 2027 Results; Updates Fiscal 2027 Guidance (press release)
- Q2 fiscal 2027 revenue $358 million, +9% reported and +10.0% organic; first-half revenue $697 million, +8% (8.0% organic).
- Organic growth by business unit in Q2: Apheresis +13.6%, MedSurg +5.5%.
- Adjusted EPS $1.35 (+6.3%); GAAP diluted EPS $1.00; adjusted gross margin 61.9% (+140 bps), helped by tariff refunds.
- Adjusted operating margin 26.3%, down 40 bps, as adjusted operating expenses rose 15.2% to $127.6 million on personnel costs and freight.
- Q2 operating cash flow $128.1 million; free cash flow $103.8 million (+$15.1 million).
- Fiscal 2027 guidance raised: reported revenue growth 8-11% (from 5-8%), organic 6-9% (from 4-7%), Apheresis now high-single-digit growth; adjusted operating margin expansion cut to 0-50 bps (from 50-100 bps); free cash flow conversion above 80%.
- CEO Chris Simon: "Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities."
- Q2 fiscal 2027 earnings call transcript
- Q2 fiscal 2027 organic revenue +10%, first half +8%; adjusted EPS $1.35 in the quarter and $2.49 in the first half, both up 6%.
- Plasma grew 18% organically in Q2 (13% in the first half) on prior share gains, strong collections and the Persona PLUS rollout; CSL contributed only a "de minimis" amount in the quarter.
- CSL win: rollout of NexSys PCS with Persona PLUS to all CSL U.S. centers expected before the end of calendar 2027; it will add "approximately 50% more volume" to Plasma; full-scale conversion began in October.
- Guidance raised to 6-9% organic and 8-11% reported growth; Apheresis to high single digits; MedSurg kept at mid-single digits; guidance includes no second-half plasma collections growth.
- Adjusted operating margin expansion cut to 0-50 bps because of investments ahead of plasma share gains, performance pay and freight/energy inflation; CFO says these costs are transitory and margin gains come in fiscal 2028.
- CSL ramp starts a new capex cycle: more manufacturing lines, warehousing and devices, with elevated capex over the next two years.
- MedSurg: VASCADE MVP/MVP XL growing low double digits in EP; PerQseal Elite (FDA approved) addresses a $300 million large-bore closure market; PacePro TAVR guidewire launched; Transfusion Management is 20% of BMT revenue.
- Long-term aim: "high 20s operating margins or better as we scale"; priorities are organic investment, then debt reduction and buybacks ($325 million authorization).
- Q1 fiscal 2027 earnings call transcript
- Q1 fiscal 2027 (quarter ended June 27, 2026): revenue $339 million, +6% reported and organic; adjusted EPS $1.14, +4%; guidance raised to 5-8% reported and 4-7% organic growth.
- First quarter under the new Apheresis / MedSurg segments announced June 5, 2026.
- MedSurg revenue $148 million (+6%): BMT +8% organic with double-digit growth in Hemostasis and Transfusion Management; Interventional Technologies back to growth (+3%), VASCADE closure up low double digits.
- Apheresis revenue $191 million (+5% reported, +6% organic); Plasma +8% organic, North American disposables up in the mid-20% range; Persona PLUS rollout "ahead of schedule" with yield gains above 5% over Persona.
- Simon says the $153 million overhang from the Whole Blood divestiture and CSL loss is now behind the company: results are "clean and recurring going forward".
- Plasma collection growth assumption kept at 0-2% although U.S. customer collections grew high single to low double digits; Europe now 20% of collection volume and contracts are "essentially all" global.
- TEG: 85/15 disposables/capital, roughly $400 million TAM about 60% penetrated, 80% market share.
- Capital: $100 million of revolver repaid, net leverage about 2.69x at quarter end; focus is organic growth, with M&A not "off the table"; Dr. Martin Medeas joined the Board.
Questions about Haemonetics
What does Haemonetics do?
Haemonetics is a Boston-based medical technology company. It sells plasma collection systems to plasma fractionators, apheresis products to blood centers, and hospital technologies such as vascular closure, hemostasis testing and transfusion software in approximately 90 countries.
What is Haemonetics' revenue?
Net revenues were $1,334.0 million in fiscal 2026 (52 weeks to March 28, 2026), down 2.0%. In Q2 fiscal 2027 revenue was $357.8 million, up 9.3%, and fiscal 2027 guidance calls for 8-11% reported growth.
How many employees does Haemonetics have?
Haemonetics employed the full-time equivalent of 3,009 people at March 28, 2026, about 78% in North America.
What is Haemonetics' strategy?
It is focusing on Plasma and MedSurg as growth engines, rolling out NexSys PCS with Persona PLUS across CSL's U.S. centers by the end of calendar 2027, launching new vascular closure and guidewire products, and aiming for high 20s operating margins as it scales.
Who leads Haemonetics?
Christopher A. Simon is President and Chief Executive Officer, and James C. D'Arecca is Executive Vice President and Chief Financial Officer.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)